Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection
Plain-language summary
This trial is testing Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection for patients with adult T-cell leukemia/lymphoma (ATLL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection (COMBINATION_PRODUCT): In a previous study Dolutegravir was able to reduce HTLV-1 proviral load, but a few patients did not respond to therapy. We intend to use a combination of Dolutegravir + TDF to improve the response rate. There is no previous evidence on the use of such combination for treating HTLV-1 infection. | Dolutegravir (DTG) (DRUG): Active comparator will be DTG, 50 mg/day
Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details